Co-chair Prof Ron Grunstein will begin by briefly outlining the clinical importance of the orexin/hypocretin system. A/Prof Laura Jacobson will provide an overview of the orexin/hypocretin system, and its potential as a pharmacological target in disorders affecting sleep, wake, and the ageing brain. Dr Camilla Hoyos will present evidence for the use of orexin/hypocretin antagonists in insomnia and ageing. Dr Julia Chapman will present the latest research on orexin/hypocretin agonists in disorders of excessive hypersomnolence. The session will conclude with a panel discussion on the clinical and future implications of manipulating the orexin/hypocretin system.

This session lasts approximately 90 minutes and earns 1.5 CPD Credit Hours.

The enrolment cost is $30 for ASA members and $60 for others.